Cargando...

Novel Experimental Drugs for Treatment of Multiple Myeloma

Multiple myeloma (MM) is the second most frequent hematological malignancy characterized by bone marrow aberrant plasma cells proliferation leading to a genetic complex and heterogeneous disease, with a median survival ranging from two to more than 10 years. By using new drugs such as proteasome inh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Exp Pharmacol
Autores principales: Offidani, Massimo, Corvatta, Laura, Morè, Sonia, Olivieri, Attilio
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove 2021
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955760/
https://ncbi.nlm.nih.gov/pubmed/33727866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JEP.S265288
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!